A Boceprevir Failure in a Patient Infected with HCV Genotype 1G: Importance and Limitations of Virus Genotyping Prior to HCV Protease-Inhibitor-Based Therapy. Issue 4 (May 2013)

• Record Type: Journal Article
• Authors: Cento, Valeria; Landonio, Simona; De Luca, Francesca; Maio, Velia C Di; Micheli, Valeria; Mirabelli, Carmen; Niero, Fosca; Magni, Carlo; Rizzardini, Giuliano; Perno, Carlo F; Ceccherini-Silberstein, Francesca
• Is Part Of: Antiviral therapy. Volume 18:Issue 4(2013)
• Page Start: 1
• Page End: 5
• Publication Date: 2013-05
• Subjects: Antiviral agents -- Periodicals; Antiviral Agents -- therapeutic use; Virus Diseases -- therapy; Viruses -- drug effects; Antiviral agents; Periodical; Electronic journals; Periodicals; 616.9106
• DOI: 10.3851/IMP2529
• Languages: English
• ISSNs: 1359-6535

Abstract

A patient classified as HCV-1a-positive by both LiPA Siemens 2.0 and Abbott RealTime HCV Genotype II was instead found to be infected with HCV-1g, as determined by phylogenetic analysis of NS3 sequences. HCV-1g NS3 sequences available to date naturally harbour the resistance substitution T54S, plus P131S and L135F changes, located in the highly conserved NS3 positions within the boceprevir-binding site, as determined by structural modelling. HCV-1g NS3 sequences show some similarities to HCV-4 and are poorly responsive to interferon/ribavirin and to boceprevir/telaprevir; this patient was also a null-responder to boceprevir treatment. Baseline genotypic resistance testing may provide crucial information for the management of first-generation protease-inhibitor-based regimens, including both HCV genotype/subtype and natural resistance.